An Inactivated Antibiotic-Exposed Whole-Cell Vaccine Enhances Bactericidal Activities Against Multidrug-Resistant Acinetobacter baumannii

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shu, Meng Hooi ^a   Matrahim, Noraziyah ^b   Noramdan, Nurasyura ^a   Pang, Sui Ping ^a   Hashim, Sharina H ^a   Phoon, Wai Hong ^a   Abubakar, Sazaly ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BACTERIUM ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G; INACTIVATED VACCINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMAL; CELL LINE; CROSS REACTION; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; MACROPHAGE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; PHAGOCYTOSIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CELL LINE; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMMUNIZATION; IMMUNOGLOBULIN G; MACROPHAGES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PHAGOCYTOSIS; VACCINES, INACTIVATED;

EID: 84959320663     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22332     Document Type: Article

References (22)

1. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21(3), 538-582 (2008).
2. Kempf, M. & Rolain, J. M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. Ag. 39(2), 105-114 (2012).
3. Öncül, O. et al. Hospital-acquired infections following the 1999 Marmara earthquake. J. Hosp. Infect. 51(1), 47-51 (2002).
4. Scott, P. et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin. Infect. Dis. 44(12), 1577-1584 (2007).
5. Zavascki, A. P., Carvalhaes, C. G., Picao, R. C. & Gales, A. C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti-Infect. Ther. 8(1), 71-93 (2010).
6. European Centre for Disease Prevention and Control (ECDC). Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Annual epidemiological report. Stockholm, Sweden: ECDC (2011).
7. ECDC. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Annual epidemiological report. Stockholm, Sweden: ECDC (2013).
8. McConnell, M. J. & Pachón, J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 29(1), 1-5 (2011).
9. McConnell, M. J. et al. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect. Immun. 79(1), 518-526 (2011).
10. Billips, B. K., Yaggie, R. E., Cashy, J. P., Schaeffer, A. J. & Klumpp, D. J. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect. Dis. 200(2), 263-272 (2009).
11. Zaidi, T. S., Priebe, G. P. & Pier, G. B. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect. Immun. 74(2), 975-983 (2006).
12. Cripps, A. W., Dunkley, M. L. & Clancy, R. L. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect. Immun. 62(4), 1427-1436 (1994).
13. Cripps, A. W. et al. Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect. Immun. 74(2), 968-974 (2006).
14. National Institute of Allergy and Infectious Diseases. Types of vaccines. Available at: http://www.niaid.nih.gov/topics/vaccines/ understanding/pages/typesvaccines.aspx#subunit (2012). Accessed: 2nd April 2013.
15. McConnell, M. J., Rumbo, C., Bou, G. & Pachón, J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 29(34), 5705-5710 (2011).
16. Estein, S. M. et al. Immunogenicity of recombinant OMP31 from Brucella melitensis in rams and serum bactericidal activity against B. ovis. Vet. Microbiol. 102(3), 203-213 (2004).
17. Lindow, J. C., Fimlaid, K. A., Bunn, J. Y. & Kirkpatrick, B. D. Antibodies in action: role of human opsonins in killing Salmonella enterica serovar typhi. Infect. Immun. 79(8), 3188-3194 (2011).
18. Barnes, M. G. & Weiss, A. A. Activation of the complement cascade by Bordetella pertussis. FEMS Microbiol. Lett. 220(2), 271-275 (2003).
19. Pier, G. B., Thomas, D., Small, G., Siadak, A. & Zweerink, H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M and A against Pseudomonas aeruginosa lipopolysaccharide. Infect. Immun. 57(1), 174-179 (1989).
20. Misbah, S., AbuBakar, S., Hassan, H., Hanifah, Y. A. & Yusof, M. Y. Antibiotic susceptibility and REP-PCR fingerprints of Acinetobacter spp. isolated from a hospital ten years apart. J. Hosp. Infect. 58, 254-261 (2004).
21. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests, 11th ed. Approved standard M02-A11. Wayne, Pennsylvania: CLSI (2012).
22. Shu, M. H., Appleton, D., Zandi, K. & AbuBakar, S. Anti-inflammatory, gastroprotective and anti-ulcerogenic effects of red algae Gracilaria changii (Gracilariales, Rhodophyta) extract. BMC Complem. Altern. M. 13(1), 61 (2013).